EYLEA^® (aflibercept) Injection sBLA for Every 16-Week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review

Regeneron Pharmaceuticals, Inc. announced the US FDA has accepted for review the EYLEA® Injection supplemental Biologics License Application for an every 16-week 2 mg dosing regimen in patients with diabetic retinopathy.